Digital Tools for Allergic Rhinitis (DMAR Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: QHSLab, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This study aims to evaluate the effectiveness of digital tools in managing allergic rhinitis (AR) in primary care settings. AR is a common condition that affects many people's quality of life. The study will test whether digital tools, such as the QHSLab platform, can help patients better control their symptoms, improve adherence to treatment, and enhance overall well-being. The trial will compare two groups: one using standard care and the other using both standard care and digital tools. Participants will be monitored over 12 months, and the study will measure changes in symptom severity, treatment adherence, quality of life, and healthcare usage. The study will also gather feedback from patients and healthcare providers about their experience with the digital tools. The digital tools used in this study are designed to help patients manage their AR more effectively by providing regular symptom assessments, medication reminders, and personalized feedback based on their health data. This summary ensures the information is clear and straightforward for patients, families, and healthcare providers while maintaining compliance with IRB guidelines.

Eligibility Criteria

This trial is for individuals with allergic rhinitis, commonly known as hay fever or allergies, who may also have sinus infections. To join, participants should be seeking to manage their symptoms in a primary care setting and willing to use digital tools alongside standard care.

Inclusion Criteria

I am between 18 and 65 years old.

I have been diagnosed with allergies or sinus issues for over 6 months.

My allergy symptoms are severe, based on a SNOT-22 score of 20 or more.

Exclusion Criteria

I am between 18 and 65 years old.

I had surgery for nasal polyps in the last 3 months.

Participant Groups

The study tests the effectiveness of QHSLab's digital tools (AME and ARIS) in managing allergic rhinitis over 12 months. It compares standard care alone versus standard care plus these digital aids by measuring symptom control, adherence to treatment, quality of life, and healthcare usage.

2Treatment groups

Experimental Treatment

Active Control

Group I: Standard Care plus Digital Tools (QHSLab with AME and ARIS) groupExperimental Treatment1 Intervention

Participants in this arm will receive the standard care for managing allergic rhinitis, which includes regular clinical evaluations and treatments as determined by their healthcare provider. In addition, they will be provided access to the QHSLab digital platform, which includes the Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS) tools. These tools will offer continuous symptom monitoring, medication reminders, and personalized feedback based on patient-reported data. The intervention aims to improve symptom management, medication adherence, and quality of life over the 12-month follow-up period.

Group II: Standard Care (STC) groupActive Control1 Intervention

Participants in this arm will receive the current standard of care for managing allergic rhinitis, which includes clinical evaluations, diagnosis, and treatments based on the healthcare provider's assessment. Treatment options may include medications such as intranasal corticosteroids, antihistamines, or decongestants, as typically prescribed for allergic rhinitis management. The standard care group will not have access to the digital tools provided in the experimental arm, but their care will follow established guidelines and practices for allergic rhinitis management.